在这里，研究人员开发了一种基于细菌囊泡的免疫抑制逆转和优化的抗原修饰平台 (BROAD-CAR ...

近日，哈医大肿瘤医院郑桐森教授团队在肿瘤免疫治疗领域取得重要进展，研究论文《Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy》于1月7日在线发表在《Nature Biomedical ...

近日，哈医大肿瘤医院郑桐森教授团队在肿瘤免疫治疗领域取得重要进展，研究论文《Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy》于1月7日在线发表在《Nature Biomedical Engineering》（2026，IF:26.7）。研究团队成功开发出基于细菌外膜囊泡（OMV）的新型CAR-T赋 ...

Trojan horse” approach may enable ‘antigen-independent’ therapy with potential to treat cancers not traditionally amenable to immunotherapy.

UT Southwestern Medical Center researchers have discovered that increasing the levels of a protein called BACH2 makes ...

LONDON and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made ...

CAR T cell therapy has transformed blood cancer treatment, but success in solid tumors remains limited by major challenges such as on-target/off-tumor toxicity, poor tumor infiltration, and an ...

CAMBRIDGE, Mass., Oct. 29, 2025 /PRNewswire/ -- CREATE Medicines, Inc. (formerly Myeloid Therapeutics) today announced new preclinical data for RetroT, the company's fully RNA-encoded, site-specific ...